All News

A recently published study looked to evaluate the effect of a single dose of nilotinib (Tasigna) in patients with PD. While nilotinib is FDA approved for the treatment of adult patients with chronic myeloid leukemia and not PD, the drug is able to penetrate the blood-brain barrier and reduce inflammation as well as lower levels of a toxic protein that prevents the brain from utilizing dopamine stored in vessels in areas of the brain that may control movement.

Researchers of a recently published study used preclinical behavioral models of migraine to determine that the application of calcitonin gene-related peptide (CGRP) to the dura mater, or the protective outer layer between the skull and the brain, in mice triggers pain responses only in females.

Rising consumerism, new competition, and payment models designed to keep patients out of acute care are forcing hospital-centric enterprises to rethink their delivery models. Organizations that excel in building integrated care delivery ecosystems and lasting consumer relationships based on a differentiated brand promise and superior outcomes will be the ones that find success.

The American College of Physicians has updated their breast cancer screening guidelines to recommend that women of average risk of breast cancer get a mammogram at age 50 and every other year; the FDA advised clinicians against aburptly halting opioid prescribing for patients with chronic pain; New York’s mayor declared a public health emergency over the state’s measles outbreak.

The program comes as Congress has singled out the cost of insulin in its scrutiny of drug prices. Patients with type 1 diabetes cannot survive without the hormone, and press reports have highlighted the plight of young adults who ration insulin after they reach age 26 and cannot stay on family insurance plans.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo